B
BD5
vs
D
DAX Index
Over the past 12 months, BD5 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +12% growth.
Stocks Performance
BD5 vs DAX Index
Performance Gap
BD5 vs DAX Index
Performance By Year
BD5 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
